VEGFA and myocardial ischemia: Luseogliflozin showed to upregulate the expression of vascular endothelial growth factor (VEGF)-α in the kidney after ischemia–reperfusion injury in non-diabetic mice [165]; at the same time, Nikolaou et al. demonstrated the protective role of chronic administration of empagliflozin in the myocardial ischemia–reperfusion injury in diabetic mice, sustained by the upregulation of VEGF pathway [101].